• Blog
  • Chronic Idiopathic Constipation (CIC) Drugs Market Report

    Chronic Idiopathic Constipation (CIC) Drugs Market Report

    Chronic Idiopathic Constipation (CIC) Drugs Market Report
    Report code - SR1553 Delivery - 2 Weeks
    Get Free Sample |
    Chronic Idiopathic Constipation (CIC) Drugs Market Trends, Dynamics & Market Insights
    See more...

    Impact of COVID-19 on Chronic Idiopathic Constipation (CIC) Drugs Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Chronic Idiopathic Constipation (CIC) Drugs Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from USD 4.1 billion in 2020 to USD 6.0 billion by 2026 at a CAGR of around 6.8% during the forecast period.

    Figure: Chronic Idiopathic Constipation (CIC) Drugs Market Size, 2020-2026 (USD Billion)

    Chronic-Idiopathic-Constipation-(CIC)-Drugs-Market-Forecast

    Wish to get a free sample? Register Here

    What is constipation?

    Constipation is defined as a health condition with decreased stool frequency or issues en passant stool. Reduced or tough stool passage is in the course of hard lumpy stools, straining, incomplete bowel actions, incomplete evacuation, and also the necessity for manual elimination of stool. Chronic idiopathic constipation (CIC) is defined as a persistent or extreme continuation of the above-mentioned signs and symptoms.

    Key Players

    Key players operating in the Chronic Idiopathic Constipation (CIC) Drugs market are-

    • Actavis Generics (US)
    • The Chugai Pharmaceutical Co., Ltd (Japan)
    • Ferring International Center, S.A. (Switzerland)
    • Synergy Pharmaceuticals (US)
    • Pfizer Inc. (US)
    • GlaxoSmithKline plc (UK)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Sanofi S.A. (France)
    • Bayer AG (Germany)
    • Salix Pharmaceuticals, Inc. (US)
    • Sucampo Pharmaceuticals, Inc. (US)
    • Ironwood Pharmaceuticals, Inc (US)
    • Progenics Pharmaceuticals, Inc. (US).

    Market Dynamics

    The growth of the chronic idiopathic constipation (CIC) drugs market is primarily driven by increasing incidences of chronic constipation health disorder. Expanding geriatric populace across geographies coupled with rising spending on healthcare is expected to propel the market growth at a significant rate during the review period. Additionally, a growing emphasis on research and development activities for novel drug development is likely to create lucrative opportunities for the market players during the review period.

    Segments' Analysis

    End-User Trends

    By end-user, the chronic idiopathic constipation (CIC) drugs market has been bifurcated into hospitals & clinics, ambulatory surgical centers, long-term care centers, and others. Under these, the hospitals & clinics segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period.

    Regional Trends

    By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of chronic constipation particularly among the geriatric populace coupled with the presence of key market players such as Actavis Generics (US) and Pfizer Inc. (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding CIC drugs coupled with the rising geriatric population in developing countries, particularly China and India.

    COVID-19 Impact on Chronic Idiopathic Constipation (CIC) Drugs Market

    The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the product supply for a short period and thus, affected the market growth.

    Critical Questions Answered in the Report

    • What are the key trends in the Chronic Idiopathic Constipation (CIC) Drugs market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the Chronic Idiopathic Constipation (CIC) Drugs market?
    • What are the key strategies adopted by the major vendors to lead in the Chronic Idiopathic Constipation (CIC) Drugs market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Target Audience

    Here is the list of the group of customers that the Chronic idiopathic constipation (CIC) Drugs Market hopes to have the greatest opportunity to convert-

    • Chronic idiopathic constipation (CIC) Drugs distributors
    • Chronic idiopathic constipation (CIC) Drugs suppliers
    • Chronic Idiopathic Constipation (CIC) Drugs manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The chronic idiopathic constipation drugs market is expected to witness an impressive growth of 6.8% CAGR in the coming years.

    Actavis Generics (US), The Chugai Pharmaceutical Co., Ltd (Japan), Ferring International Center, S.A. (Switzerland), Synergy Pharmaceuticals (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Bayer AG (Germany), Salix Pharma-ceuticals, Inc. (US), Sucampo Pharmaceuticals, Inc. (US), Ironwood Pharmaceuticals, Inc (US) and Progenics Pharmaceuticals, Inc. (US) are among the key players in the chronic idiopathic constipation drugs market.

    The chronic idiopathic constipation drugs market size is expected to reach USD 6.0 billion in the foreseeable future.

    The hospitals & clinics segment is expected to register significant growth in the chronic idiopathic constipation drugs market in the coming years.

    North America accounted for the largest share in the chronic idiopathic constipation drugs market in 2020.

    Chronic idiopathic constipation (CIC) Drugs distributors, Chronic idiopathic constipation (CIC) Drugs suppliers, Chronic Idiopathic Constipation (CIC) Drugs manufacturers, Logistics organizations, Government bodies are the target audience in the chronic idiopathic constipation drugs market.

    //